Gilead Emphasizes Unique Ways To Hire Top Talent

When Jamari Brooks was looking for a new job last fall, he knew he wanted his future employer to have a few key qualities. As he perused pharmaceutical companies' job postings, he kept a look out for diversity in leadership, the potential for personal career growth and a commitment to helping improve the lives of people and the health of the world

It was through Gilead's relationship with the National Black MBA Association that he encountered the company. Gilead checked all his boxes, but it was the interview process that really cinched the deal for Jamari. Jasmine Pree Hameth, Senior Director of Corporate Function and Strategic Talent Sourcing at Gilead, connected him with diverse, executive-level Gilead staff so he could learn about their experiences at the company - which, Jamari says, had an impact.

"Before I even started, Jasmine set me up with people within Gilead that I could build networks with and potentially work with," Jamari says. "It didn't feel like they were checking a box hiring me. It was an authentic recruitment process. I thought ‘this is where I need to be, no question about it'."

Today, Jamari works in Sourcing and Procurement at Gilead, where he helps research teams identify and purchase equipment that allows them to create new medications. His experience joining Gilead represents one of several efforts the company is focusing on to hire new, top talent with the belief that diversity drives performance and innovation and helps shape an inclusive culture.

For the past three years, Gilead's Talent Acquisition team has focused on a multi-year set of commitments to increase diversity within the organization's workforce by building relationships with, and by hiring diverse talent from, universities and institutions such as the National Black MBA Association, the National Society of Black Engineers, the National Sales Network and a number of Historically Black Colleges and Universities.

As another part of the recruiting strategy, Gilead also launched a Programming Academy, a four-month program that draws in early and pre-career underrepresented and diverse talent to train them in how to do pharmaceutical programming. This ranges from the curation of data, which means handling data gaps and errors, and analytical programming, which reveals scientific discoveries embedded in data.

Talent Acquisition's efforts are largely focused on building partnerships outside of Gilead's backyard, to ensure that the California-based company finds diverse talent across the United States. Jamari works remotely from Chicago, and the Programming Academy is based in North Carolina.

Gilead's Programming Academy
The Programming Academy is how Adashi Odama discovered Gilead. She graduated with a master's degree in public health last year, and as part of her job hunt attended a Gilead virtual event. It sparked her interest, and when she saw an application online for the academy, she applied. "I always like a new environment, something that's a challenge," she explains. "I'm very interested in data analysis and I do a lot of programming that involves statistics. I thought I could go for it."

Michael Neece, the head of Gilead's Programming Academy, says he created it to fill the gaps in knowledge that he recognized when he started in the pharmaceutical programming world. "We just kind of stumbled into the industry," he says of himself and the two chief instructors. "Hopefully, we're removing some of the barriers to being really successful in the program by having created what we wish we had when we joined."

The Academy offered Adashi a unique opportunity to learn on the job, tackling everything from clinical trials to drug production to Food and Drug Administration rules and regulations. She also learned SAS, a programming software she previously had no experience with.

The training nurtured Adashi's love of statistics and allowed her to focus in on her desire to make a difference. "Once you start to get into statistics, you realize that it tells you pretty much everything," she says. "I think it's a very tangible way to understand health problems, to see exactly what needs to be fixed or what should be addressed."

When Adashi graduated from the Programming Academy last October, she was offered a job with Gilead's inflammation team. "It definitely prepared me for what I'm currently doing," she says of the academy. "I was given the confidence to believe that I could be successful. It laid a very solid foundation, and now I feel I'm able to learn more."

Adashi and Jamari came from different backgrounds, pursued different degrees and lived in different parts of the country. But their commitment to personal growth, and to doing work that makes a difference, is a uniting force that brought them to Gilead.

"Gilead is a company that really values innovation and empowering employees," Jamari says. "You can create a fingerprint at the company quickly. It's been awesome to experience."

Learn more about Gilead Careers.

Originally published by Gilead Sciences

Gilead Sciences, Wednesday, May 10, 2023, Press release picture

View additional multimedia and more ESG storytelling from Gilead Sciences on 3blmedia.com.

Contact Info:
Spokesperson: Gilead Sciences
Website: https://www.3blmedia.com/profiles/gilead-sciences
Email: info@3blmedia.com

SOURCE: Gilead Sciences



View source version on accesswire.com:
https://www.accesswire.com/753946/Gilead-Emphasizes-Unique-Ways-To-Hire-Top-Talent

News Provided by ACCESSWIRE via QuoteMedia

GILD
The Conversation (0)
CHMP Adopts Positive Opinion Recommending Hepcludex®  for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus

CHMP Adopts Positive Opinion Recommending Hepcludex® for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus

-- If Granted by the European Commission, Hepcludex will Become the Only Approved Treatment for HDV in the EU -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive... Keep Reading...
Gilead Remains Steadfast in Support for Hepatitis C Elimination Efforts

Gilead Remains Steadfast in Support for Hepatitis C Elimination Efforts

The recent national conversation on hepatitis C (HCV) is an encouraging step towards viral hepatitis elimination in the U.S. With its long history of leadership in viral hepatitis, Gilead continues to support efforts that focus on HCV elimination. Gilead is proud that its medicines have treated... Keep Reading...
Gilead Sciences Announces First Quarter 2023 Financial Results

Gilead Sciences Announces First Quarter 2023 Financial Results

Product Sales Excluding Veklury Increased 15% Year-Over-Year to $5.7 billion Biktarvy Sales Increased 24% Year-Over-Year to $2.7 billion Oncology Sales Increased 59% Year-Over-Year to $670 million Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first... Keep Reading...
Gilead Sciences Releases Inaugural ESG Impact Report

Gilead Sciences Releases Inaugural ESG Impact Report

Gilead Sciences recently released its inaugural Environmental, Social and Governance (ESG) Impact Report. This is an evolution of our traditional Year in Review, and uses the ESG framework to highlight the successes and achievements of the prior yearThough the report itself is new, our... Keep Reading...
abigail echo-hawk

CORRECTION: Contakt World Becomes Data Partner for Health Equity Tracker Project to Improve the Collection of De-Identified Racial & Ethnic Minority Data Using Smart Health RM, Engagency, and Future Services

Enables Contakt World mission to improve health equity and reduce disparities in the fight against Covid-19 and all diseases via award-winning SaaS platformThis document corrects and updates the final paragraph in the body of this news release. No other changes were required in this... Keep Reading...
Quantum Biopharma

Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock

Reward to be Paid if Information Contributes Significant Evidence Leading to a Trial Victory or Settlement in Landmark USD $700 Million+ Lawsuit

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol... Keep Reading...
Imagion Biosystems

Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway

Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging technology, is pleased to provide shareholders with a progress update regarding the Company’s business and... Keep Reading...
Stethoscope on stacked gold coins, symbolizing healthcare costs or medical finance.

Trump Tariffs to Raise US Medical Device Costs, Hospitals Hold Off on Stockpiling

President Donald Trump’s new round of tariffs —this time targeting copper— has intensified concerns about rising costs across key sectors, including healthcare. But despite significant price pressures on steel, aluminum, and now copper, all vital to medical device production, there is no... Keep Reading...
Actinogen

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline

Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer’s disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July. This... Keep Reading...
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access... Keep Reading...
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will... Keep Reading...

Latest Press Releases

Related News